simoctocog alfa - search results

New Zealand - English - Medsafe (Medicines Safety Authority)

nuwiq

octapharma new zealand ltd - simoctocog alfa 2000 [iu] - powder for injection - 2000 iu - active: simoctocog alfa 2000 [iu] excipient: arginine hydrochloride calcium chloride dihydrate poloxamer 188 sodium chloride sodium citrate dihydrate sucrose water for injection - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (greater than or equal to 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

nuwiq

octapharma new zealand ltd - simoctocog alfa 250 [iu] - powder for injection - 250 iu - active: simoctocog alfa 250 [iu] excipient: arginine hydrochloride calcium chloride dihydrate poloxamer 188 sodium chloride sodium citrate dihydrate sucrose water for injection - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (greater than or equal to 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

nuwiq

octapharma new zealand ltd - simoctocog alfa 500 [iu] - powder for injection - 500 iu - active: simoctocog alfa 500 [iu] excipient: arginine hydrochloride calcium chloride dihydrate poloxamer 188 sodium chloride sodium citrate dihydrate sucrose water for injection - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (greater than or equal to 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

nuwiq, human cell line recombinant human factor viii (human-cl rhfviii), 250iu, powder and solvent for solution for injection. vial of powder and prefilled wfi syringe

octapharma australia pty ltd - simoctocog alfa, quantity: 250 iu - injection, powder for - excipient ingredients: sucrose; sodium chloride; sodium citrate dihydrate; poloxamer; calcium chloride dihydrate; arginine hydrochloride - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand?s disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

nuwiq, human cell line recombinant human factor viii (human-cl rhfviii), 2000iu, powder and solvent for solution for injection. vial of powder and prefilled wfi syringe

octapharma australia pty ltd - simoctocog alfa, quantity: 2000 iu - injection, powder for - excipient ingredients: arginine hydrochloride; calcium chloride dihydrate; sucrose; sodium chloride; poloxamer; sodium citrate dihydrate - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand?s disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

nuwiq, human cell line recombinant human factor viii (human-cl rhfviii), 500iu, powder and solvent for solution for injection. vial of powder and prefilled wfi syringe

octapharma australia pty ltd - simoctocog alfa, quantity: 500 iu - injection, powder for - excipient ingredients: arginine hydrochloride; poloxamer; calcium chloride dihydrate; sodium citrate dihydrate; sucrose; sodium chloride - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand?s disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

nuwiq, human cell line recombinant human factor viii (human-cl rhfviii), 1000iu, powder and solvent for solution for injection. vial of powder and prefilled wfi syringe

octapharma australia pty ltd - simoctocog alfa, quantity: 1000 iu - injection, powder for - excipient ingredients: poloxamer; arginine hydrochloride; sucrose; sodium chloride; sodium citrate dihydrate; calcium chloride dihydrate - treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (>= 2 years) and adult patients with haemophilia a (congenital factor viii deficiency). nuwiq does not contain von willebrand factor and is thus not indicated to treat von willebrand?s disease.

Singapore - English - HSA (Health Sciences Authority)

nuwiq powder and solvent for solution for injection 1000 iu

wellchem pharmaceuticals pte ltd - human coagulation factor viii (rdna, simoctocog alfa) - injection, powder, for solution - human coagulation factor viii (rdna, simoctocog alfa) 1000 iu fviii:c / vial

Singapore - English - HSA (Health Sciences Authority)

nuwiq powder and solvent for solution for injection 2000 iu

Singapore - English - HSA (Health Sciences Authority)

nuwiq powder and solvent for solution for injection 250 iu